Evaxion A/S (EVAX)

Market Cap	163.05M +1,291.4%
Revenue (ttm)	7.53M +125.1%
Net Income	-7.71M
EPS	-1.20
Shares Out	41.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,415
Open	4.000
Previous Close	4.000
Day's Range	3.770 - 4.091
52-Week Range	1.200 - 12.150
Beta	0.32
Analysts	Strong Buy
Price Target	11.67 (+198.47%)
Earnings Date	Mar 5, 2026

About EVAX

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX
• Website: https://evaxion.ai

Financial Performance

In 2025, Evaxion's revenue was $7.53 million, an increase of 125.12% compared to the previous year's $3.34 million. Losses were -$7.71 million, -27.07% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $11.67, which is an increase of 198.47% from the latest price.

Price Target

$11.67

(198.47% upside)

Analyst Consensus: Strong Buy